Reporting owner · CIK 0001725092

Lin Shao-Lee

SEC Form 4 history for the last 180 days across 1 company, 2 transactions and 1 filing.

CEOChief Executive OfficerCue Biopharma, Inc.
Open-market transaction mix0% buys0 buys · 2 sales

Period: Last 180 days

Trade dates in this period: Oct 12, 2026 – Oct 12, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$00 purchases
Selling$305k2 sales
Net value−$305kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Lin Shao-Lee transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
CUECue Biopharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$30.5kView disclosure →
CUECue Biopharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$275kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at Cue Biopharma, Inc. on Oct 12, 2026 valued at $30,490.35.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Oct 202602$0$305,490.35−$305,490.35

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$153k
Median P/S size$153k
Direct2
Indirect0
Oct 12, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

2 observations · Oct 12, 2026 – Oct 12, 2026. Window ends at the latest available report, not today.

Selected observation · Oct 12, 2026694,908 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Oct 12, 2026695,995Oct 14, 2026View transaction
Oct 12, 2026694,908Oct 14, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Lin Shao-Lee Insider Activity FAQ

SEC Form 4 context

Who is Lin Shao-Lee?

Lin Shao-Lee is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001725092.

Which companies has Lin Shao-Lee reported transactions for?

Cue Biopharma, Inc., ACELYRIN, Inc.

When was Lin Shao-Lee's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Lin Shao-Lee's latest insider sale?

The insider reported a sale at Cue Biopharma, Inc. on Oct 12, 2026 valued at $30,490.35.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.